Scalper1 News
The European Commission (EC) approved Gilead Sciences’ (GILD) drug Zydelig for two blood cancers on Friday, sending Gilead stock up as much as 1.9%, though shares were flat in midday trading in the stock market today. The EC approved the drug for chronic lymphocytic leukemia and follicular lymphoma. For the former, it is to be used in combination with Rituxan (sold jointly by Roche and Biogen Idec (BIIB), and for the latter by itself. The move Scalper1 News
Scalper1 News